Xlife Sciences AG (XSWX:XLS) Dividends Received


XSWX:XLS Xlife Sciences AG XSWX:XLS
53 GF Score
Price CHF20.20
GF Value CHF7.29
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Xlife Sciences AG Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

XSWX:XLS
53GF Score
Xlife Sciences AG XSWX:XLS
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Xlife Sciences AG (XSWX:XLS) Overvalued in 2026?

Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued. The current stock price of CHF20.20 is trading 177.1% above its estimated GF Value™ of CHF7.29. GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.

Key valuation signals for XSWX:XLS:

  • Dividends Received:
  • GF Value™: CHF7.29 vs. price of CHF20.20 (177.1% above fair value)
  • GF Score™: 53/100 with 10 warning signs

No single metric tells the full story. See the XSWX:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Xlife Sciences AG Business Description

Other Exchanges XLSz:UKXLS:Germany
Address Talacker 35, Zurich, CHE, 8001
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
53GF Score

Get the complete analysis for XSWX:XLS

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF20.20
Price
CHF7.29
GF Value